Mo1362 IDENTIFYING KEY FACTORS FOR THE EFFECTIVENESS OF PANCREATIC CANCER SCREENING IN HIGH-RISK INDIVIDUALS: A MODEL-BASED ANALYSIS

Koopmann, Brechtje D M; Dirksmeier-Harinck, Femme; Kroep, Sonja; Konings, Ingrid C.; Naber, Steffie K.; Lansdorp–Vogelaar, Iris; Fockens, Paul; Hooft, Jeanin E. van; Cahen, Djuna L.; Ballegooijen, Marjolein van; Kok, Inge de; Bruno, Marco J.

doi:10.1016/s0016-5085(20)32839-0

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, to date, the cost-effectiveness of only conventional non-specific risk factors has been considered. A 2021 microsimulation screening analysis model investigated the impact of relevant uncertainties on the effectiveness of pancreatic cancer screening and showed that test specificity had higher influence than sensitivity[ 40 ]. Growing evidence compels a consideration of middle-aged and older adults with PPDM and/or incidentally found fatty pancreas disease as specific populations at very high risk of developing pancreatic cancer.…”

Section: Discussionmentioning

confidence: 99%

Post-pancreatitis diabetes mellitus and excess intra-pancreatic fat deposition as harbingers of pancreatic cancer

Petrov¹

2021

WJG

View full text Add to dashboard Cite

Progress in the fight against pancreatic cancer has been hampered by many factors. One of them is the inability to detect the disease early in overwhelming majority of patients. The present paper outlines a novel way in which progress could be accelerated. This includes a focus on two harbingers—post-pancreatitis diabetes mellitus and excess intra-pancreatic fat deposition—that converge at affecting the tumor macroenvironment and microenvironment specifically in the pancreas, not other organs. The two entities have the potential to be incorporated into future screening strategies with a view to early detecting of pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Post-pancreatitis diabetes mellitus and excess intra-pancreatic fat deposition as harbingers of pancreatic cancer

Petrov¹

2021

WJG

View full text Add to dashboard Cite

show abstract

“…Intraductal papillary mucinous neoplasm (IPMN) is now frequently encountered with the widespread use of computed tomography (CT) and magnetic resonance imaging (MRI) 1–5 . However, when IPMN is detected, it is difficult to decide which patients should be followed up with imaging for longer periods because the evidence regarding surveillance strategies is graded as very low‐quality 3,4,6–9 …”

Section: Introductionmentioning

confidence: 99%

Identifying predictors for comorbidities related mortality versus pancreatic cancer related mortality in patients with intraductal papillary mucinous neoplasm

Sekine,

Nagata,

Hisada

et al. 2024

UEG Journal

View full text Add to dashboard Cite

BackgroundsFew data are available for surveillance decisions focusing on factors related to mortality, as the primary outcome, in intraductal papillary mucinous neoplasm (IPMN) patients.AimsWe aimed to identify imaging features and patient backgrounds associated with mortality risks by comparing pancreatic cancer (PC) and comorbidities.MethodsWe retrospectively conducted a multicenter long‐term follow‐up of 1864 IPMN patients. Competing risk analysis was performed for PC‐ and comorbidity‐related mortality.ResultsDuring the median follow‐up period of 5.5 years, 14.0% (261/1864) of patients died. Main pancreatic duct ≥5 mm and mural nodules were significantly related to all‐cause and PC‐related mortality, whereas cyst ≥30 mm did not relate. In 1730 patients without high‐risk imaging features, 48 and 180 patients died of PC and comorbidity. In the derivation cohort, a prediction model for comorbidity‐related mortality was created, comprising age, cancer history, diabetes mellitus complications, chronic heart failure, stroke, paralysis, peripheral artery disease, liver cirrhosis, and collagen disease in multivariate analysis. If a patient had a 5 score, 5‐ and 10‐year comorbidity‐related mortality is estimated at 18.9% and 50.2%, respectively, more than 7 times higher than PC‐related mortality. The model score was also significantly associated with comorbidity‐related mortality in a validation cohort.ConclusionsThis study demonstrates main pancreatic duct dilation and mural nodules indicate risk of PC‐related mortality, identifying patients who need periodic examination. A comorbidity‐related mortality prediction model based on the patient's age and comorbidities can stratify patients who do not require regular tests, especially beyond 5 years, among IPMN patients without high‐risk features.Clinical trial registrationT2022‐0046.

show abstract

Mo1362 IDENTIFYING KEY FACTORS FOR THE EFFECTIVENESS OF PANCREATIC CANCER SCREENING IN HIGH-RISK INDIVIDUALS: A MODEL-BASED ANALYSIS

Cited by 2 publications

References 0 publications

Post-pancreatitis diabetes mellitus and excess intra-pancreatic fat deposition as harbingers of pancreatic cancer

Post-pancreatitis diabetes mellitus and excess intra-pancreatic fat deposition as harbingers of pancreatic cancer

Identifying predictors for comorbidities related mortality versus pancreatic cancer related mortality in patients with intraductal papillary mucinous neoplasm

Contact Info

Product

Resources

About